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Purpose: The aim of this study is to evaluate long-term survival and prognostic factors for radio-frequency ablation (RFA) 
in colorectal liver metastases.
Methods: We retrospectively reviewed 35 colorectal liver metastases patients who underwent RFA between 2004 and 2008. 
We analyzed survival after RFA and prognostic factors for survival.
Results: Of the 35 patients, 23 patients were male and 12 were female. Their mean age was 62.40 ± 12.52 years. Mean over-
all survival was 38.8 ± 4.6 months, and mean progression free survival was 19.9 ± 3.4 months. Three- and 5-year overall 
survival rates were 42.7 ± 0.1% and 26.0 ± 0.1%, respectively. Three- and 5-year progression-free survival rates were 19.6 ± 
0.1% and 4.9 ± 0.04%, respectively. Overall survival and progression-free survival were significantly improved in male and 
in patients with carcinoembryonic antigen (CEA) ≤ 100 ng/mL, carbohydrate antigen (CA) 19-9 ≤ 100 ng/mL, absence of 
extrahepatic disease, and a unilobar hepatic lesion. In addition, progression-free survival was improved in patients with a 
solitary hepatic lesion. On the multivariate analysis, significant survival factors were the absence of extrahepatic disease 
and the presence of a unilobar hepatic lesion.
Conclusion: RFA for colorectal liver metastases is an effective treatment option in male patients and in patients with CEA 
or CA19-9 ≤ 100, absence of extrahepatic disease, a solitary hepatic lesion, and a unilobar hepatic lesion.
Keywords: Radiofrequency ablation; Colorectal liver matastasis; Survival; Prognostic factor
of treatment for hepatic metastases of colorectal cancers is surgi-
cal resection [1, 6-8], with a five-year survival rate of 31-58% [2]. 
However, the percentage of surgical resections for lesions in the 
liver at diagnosis is only 10-15%, and if a hepatic resection is not 
performed, the five-year survival rate is about 1-2% [7]. Therefore, 
chemotherapy, radio-frequency ablation, transarterial chemoem-
bolization or percutaneous ethanol injection therapy has been at-
tempted in patients on whom a hepatic resection cannot be per-
formed [1, 2, 5].
Among the above treatments, radio-frequency ablation (RFA) is 
used for not only primary carcinomas but also metastatic carcino-
mas, and it is widely used for hepatic metastases of colorectal can-
cers in patients on whom a hepatic resection cannot be performed 
[7, 9]. RFA is an easily applied method because it is less invasive, 
and the risk of side effects or mortality is comparatively low com-
pared to other treatment options, including surgery. Furthermore, 
RFA can be performed repeatedly in cases of local recurrence at 
the site after RFA or at a new metastatic hepatic carcinoma lesion. 
Even though RFA has often been performed thus far for primary 
INTRODUCTION
Colorectal cancer is one of the most common cancers worldwide 
[1] and is one of the main causes of death [2]. Metastasis occurs 
in about 50% of patients with colorectal cancers [3, 4], hepatic me-
tastasis being the most common [5, 6]. Hepatic metastasis has been 
reported to be found in about 20-25% of patients with colorectal 
cancers at diagnosis. It occurs in about 20-30% of patients within 
the first 3 years of treatment for colorectal cancers [1]. The first line 
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or metastatic hepatic carcinomas in patients with fewer than 4 tu-
mors, each being smaller than 4 cm, on whom a surgical resection 
could not be performed, the applicable targets of RFA have been 
broadened [7]. However, the results reported for these treatments 
are insufficient in spite of the expansion of applicable targets [2]. 
Thus, the purpose of this study is to investigate the factors that can 
affect the survival rate of patients with hepatic metastases of colorec-
tal cancers after RFA treatment.
METHODS
This study was retrospectively conducted on 35 patients with he-
patic metastases of colorectal cancers. The patients were treated 
with RFA at Ewha Womans University Hospital from January 2004 
to December 2008.
Inclusion criteria in our study were as follows: (1) complete resec-
tion of the hepatic lesion was impossible, (2) recovery was consid-
ered as difficult due to age, co-morbidities or poor health condi-
tions existed even though a complete resection was possible, (3) a 
hepatic resection was not expected to lead to recovery of a patient 
with metastases of organs other than the liver, or (4) the patient 
refused surgery. However, patients were excluded from RFA (1) 
when a radical resection for the primary carcinoma was impossi-
ble, (2) when the lesion in the liver could not be detected through 
ultrasonography, (3) when a severe coagulation deficiency existed 
there were more than five metastatic lesions, or (4) when the larg-
est lesion was bigger than 5 cm.
RFA was conducted through a percutaneous approach under lo-
cal anesthesia, with some procedures being performed during sur-
gery for colorectal cancer. The device used for treatment was a ra-
dio-frequency generator with a capacity of 200 watts (Valleylab, 
Boulder, CO, USA), and an electric current was emitted, targeting 
the tissue of the tumors, by using a unipolar radio-frequency elec-
trode or expandable multi-electrode for 12-15 minutes. Response 
to treatment was evaluated using abdominal computed tomogra-
phy one month after RFA. The results were considered as complete 
necrosis when contrast enhancement was not detected during the 
arterial phase or the portal phase at the treated lesion, and the tu-
mor size was smaller. Clinical follow-up was performed every three 
months using computed tomography, and RFA was additionally 
conducted when a new tumor was found.
The effect of RFA on patients with hepatic matastases of colorec-
tal cancers was evaluated by analyzing the overall survival and the 
progression-free survival rates. Clinical characteristics, including 
gender, age, and tumor marker and histopathological characteris-
tics, such as location or clinical stage of the primary carcinoma and 
size and number of hepatic metastases, were investigated. The rela-
tionships between these characteristics and the survival rates were 
also analyzed.
The overall survival and the progression-free survival rates of the 
patients were analyzed using the Kaplan-Meier method, and the 
survival rates according to clinical or histological characteristics 
were compared using a univariate log-rank test and a multivariate 
Cox proportional hazards model. The statistical analysis was con-
ducted using SPSS ver. 16.0 (SPSS Inc., Chicago, IL, USA) for Win-
dows, and a P-value < 0.05 was considered as significant.
RESULTS
Distribution of patients
Out of the 35 patients, 23 were male and 12 were female, and their 
mean age was 62.40 ± 12.52 years (range, 35 to 81 years). Seventeen 
patients had synchronous hepatic metastases, 9 of whom were treated 
with RFA during surgery for the primary carcinoma and 7 with a 
percutaneous approach while hospitalized after surgery for the pri-
mary carcinoma; the remaining patient was treated with RFA after 
the size of the hepatic metastasis had been reduced through che-
motherapy after surgery for the primary carcinoma due to the wide-
spread hepatic metastases. Of these 17 patients, 3 had metastases 
of other organs, lung, ovary and peritoneum, respectively, besides 
the liver when diagnosed as having colorectal cancer. Eighteen pa-
tients had metachronous hepatic metastases, and the mean time 
to hepatic metastases was 16.27 ± 12.08 months (range, 2.03 to 50.4 
months).
Before hepatic metastases had occurred, four patients had metas-
tases of other organs, the lungs in two patients, the kidney in one 
patient, and the peritoneum in one patient. All 18 patients who 
had metachronous hepatic metastases were treated with RFA us-
ing the percutaneous approach a few days after the diagnosis of 
hepatic metastases (Table 1).
The primary locations of the carcinomas were the colon in 25 pa-
tients and the rectum in 10, and clinical stages were stage 1 in one 
patient, stage 2 in 4, stage 3 in 12, and stage 4 in 18 (Table 1). Out 
of these 18 patients at clinical stage 4, 16 had hepatic metastases, 1 
had peritoneal metastasis, and 1 had concurrent hepatic and pul-
monary metastases. The mean values of carcinoembryonic antigen 
(CEA) and carbohydrate antigen 19-9 (CA19-9) before RFA were 
47.19 ± 116.82 ng/mL (range, 1.3 to 561.1 ng/mL) and 1,021.63 ± 
5,200.31 U/mL (range, 0.6 to 30381.4 U/mL), respectively.
Hepatic metastases and treatment of RFA
The mean number of hepatic metastases was 1.82 ± 1.20, and there 
were 20 patients with 1 hepatic metastasis, 8 patients with 2, 1 pa-
tient with 3, 5 patients with 4 and 1 patient with 5. The mean max-
imal diameter of the carcinomas was 2.42 ± 1.11 cm (range, 1 to 5 
cm), and 26 patients had carcinomas with size < 3 cm and 9 with 
size ≥ 3 cm. Carcinomas were located at one lobe or both lobes of 
the liver in 26 and 9 patients, respectively (Table 2).
The mean number of RFAs conducted was 1.34 ± 0.64 (range, 1 
to 3 cm). Twenty-six patients were treated with an ultrasonogra-
phy-guided percutaneous approach, and 9 patients were treated 
during surgery for the primary carcinoma. There was no case that 
the hepatic resection performed prior to performing RFA. One 
patient presented with metastatic carcinomas at S4, 6, 7, and 8 and Journal of The Korean Society of
Coloproctology
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was treated at S4 while the hepatic resection was being performed 
on the right lobe.
Results of RFA
Response to the treatment was evaluated using abdominal com-
puted tomography after one month. Thirty-two patients showed 
complete necrosis of the carcinoma while 3 patients were treated 
with additional RFA due to incomplete necrosis. There were no 
significant side effects from RFA, and there were two cases of mild 
fever, one case each of hematoma and bleeding, and no cases of 
death related with RFA.
Clinical follow-up was performed using computed tomography 
every three months after treatment with RFA, and the mean follow-
up period was 30.55 ± 21.56 months (range, 2.73 to 74.2 months). 
The mean progression-free survival duration was 19.9 ± 3.4 months 
(range, 2.2 to 74.2 months). The three-year and the five-year pro-
gression-free survival rates were 19.6 ± 0.1% and 4.9 ± 0.04%, re-
spectively. In 32 patients (91.4%), recurrent hepatic carcinomas 
were detected during the clinical follow-up period, and a hepatic 
resection was performed on 2 of them; additional RFA was con-
ducted on 7. Metastases occurred in other organs besides the liver 
in 18 patients (51.4%), with pulmonary and peritoneal metastases 
being the most common. The mean overall survival duration was 
38.8 ± 4.6 months (range, 3.8 to 78.5 months), and the three-year 
and the five-year survival rates were 42.7 ± 0.1% and 26.0 ± 0.1%, 
respectively.
As a result of the univariate analysis of the dependence of the sur-
vival rates on the clinical and the histological characteristics of the 
patients, the progression-free survival rate was found to be signifi-
cantly increased when the hepatic metastasis was a single carci-
noma, and both the overall survival rates and the progression-free 
survival rates were found to be significantly increased when the 
patients were male, when CEA was ≤ 100 ng/mL or CA19-9 was 
≤ 100 U/mL, when there were no metastases in organs other than 
the liver before RFA, and when the carcinoma was localized in only 
one lobe of the liver (Table 3, Figs. 1-6). In addition, based on a mul-
tivariate analysis of these factors and the survival rates, the overall 
survival rate was found to be significantly increased (P = 0.003) 
when there was no metastases in organs other than the liver before 
RFA, and the progression-free survival rate was found to be signif-
icantly increased when the carcinoma was localized in only one 
lobe of the liver (P = 0.045, P = 0.018) (Table 4). Other factors, such 
as age, location of the carcinoma, clinical stage of the carcinoma 
and time of hepatic metastases, did not significantly associated with 
the survival rates (Table 3).
DISCUSSION
RFA is one of the treatment modalities for localized hepatic cancers, 
and it necrotizes cancer cells due to increasing the temperature of 
tissues up to 70-100°C with a radio-frequency current of 460-480 
kHz for approximately 10 to 15 minutes after setting the electrodes 
at the target carcinoma [5, 10, 11]. RFA can be effectively used to 
treat primary and metastatic hepatic carcinomas because about 
10% of their hepatic metastases are single carcinomas showing rel-
Table 2. Characteristics of the hepatic metastatic lesions
Variable No. (%)
Number
   Solitary 20 (57.1)
   Multiple  15 (42.9)
Maximum size (cm)
   <3 25 (71.4)
   ≥3 10 (28.6)
Location
   One lobe 26 (74.3)
   Both lobes   9 (25.7)
Table 1. Characteristics of patients
Variable Number (%)
Total 35 (100)
Gender
   Male 23 (65.7)
   Female 12 (34.3)
Age (yr)
   <60 13 (37.1)
   ≥60 22 (62.9)
Location of primary tumor
   Colon 25 (71.4)
   Rectum 10 (28.6)
Stage of primary tumor
   Stage I-III 17 (48.6)
   Stage IV 18 (51.4)
CEA (ng/mL)
   ≤100  31 (88.6)
   >100   4 (11.4)
CA19-9 (U/mL)
   ≤100  28 (80.0)
   >100   7 (20.0)
Liver metastasis at diagnosis
   Synchronous 17 (48.6)
   Metachronous 18 (51.4)
Extrahepatic disease
   No 28 (80.0)
   Yes   7 (20.0)
CA, carcinoembryonic antigen; CEA, carcinoembryonic antigen.Journal of The Korean Society of
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atively slow progression [11]. Even though surgical resection is pri-
marily considered in these cases, RFA is considered as a conserva-
tive method when surgery is not suitable due to age, systematically 
poor health, metastases of other organs besides the liver, or refusal 
of surgery by patients [11-13]. In addition, RFA is conducted when 
carcinomas are located at both lobes in the liver, when it is consid-
ered difficult to secure a negative resection margin, when carcino-
mas are located close to a large blood vessel, when the carcinoma 
is a recurrent metastatic carcinoma, or when the carcinoma is not 
resectable even after chemotherapy.
RFA is known to be a relatively safer treatment method than a 
hepatic resection or other localized treatment. In a study conducted 
by Rhim et al. on 1,139 patients, the mortality rate caused by RFA 
was reported as 0.09% and the side effect rate as 2.43% [14]. In an-
Table 3. Results of the univariate survival analysis
Variable
Overall survival Progression free survival
Mean (mo) 3-yr (%) 5-yr (%) P-value Mean (mo) 3-yr (%) 5-yr (%) P-value
Gender
   Male 46.0 56.2 30.9 0.026 23.8 25.4 5.1 0.047
   Female 22.9 16.7 16.7 11.3  8.3 8.3
Age (yr)
   <60 34.9 28.8 28.8 0.751 26.2 23.1 23.1 0.277
   ≥60 40.4 50.0 25.3 17.5 18.2 0
Location of primary tumor
   Colon 35.3 35.6 25.9 0.347 19.9 19.2 9.6 0.841
   Rectum 46.0 60.0 30.0 20.8 20.0 0
Stage of primary tumor
   I-III 41.2 47.1 26.9 0.699 18.8 17.6 0 0.727
   IV 35.2 38.9 24.3 21.6 22.2 11.1
CEA (ng/mL)
   ≤100  41.8 29.5 29.5 0.013 21.6 5.5 5.5 0.006
   >100 15.5 0 0 6.3 0 0
CA19-9 (U/mL)
   ≤100  44.0 53.6 32.6 0.006 22.5 24.5 6.1 0.037
   >100  18.1 14.3 0  9.3 0 0
Liver metastasis at diagnosis
   Synchronous 37.0 41.2 25.7 0.983 22.5 23.5 11.8 0.539
   Metachronous 39.2 44.4 25.4 18.1 16.7 0
Extrahepatic disease
   No 44.5 53.3 32.5 <0.001 25.6 24.5 6.1 0.049
   Yes 15.6 0 0  9.2 0 0
Number of hepatic lesions
   Solitary 46.3 60.0 36.4 0.069 25.2 29.2 5.8 0.043
   Multiple  26.9 20.0 10.0 11.9 6.7 6.7
Maximum size of hepatic lesion (cm)
   <3 38.2 44.4 26.4 0.858 19.9 19.2 4.8 0.807
   ≥3 39.0 40.0 26.7 18.6 20.0 10.0
Location of hepatic lesion
   One lobe 46.2 57.7 35.2 0.001 24.4 26.4 6.6 <0.001
   Both lobes 17.6 0 0  6.8 0 0
CA, carcinoembryonic antigen; CEA, carcinoembryonic antigen.Journal of The Korean Society of
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other study by Livraghi et al. [15] on 2320 patients, the mortality 
rate was reported as 0.3%, the serious side effect rate as 2.2%, and 
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Fig. 2. Kaplan-Meier survival based on serum carcinoembryonic antigen (CEA) levels. (A) Patients with CEA ≤ 100 ng/mL had improved overall 
survival compared with those with CEA > 100 ng/mL (41.8 vs. 15.5 mo; P = 0.013). (B) Patients with CEA ≤ 100 ng/mL had improved progression-
free survival compared with those with CEA > 100 ng/mL (21.6 vs. 6.3 mo; P = 0.006).
the mild side effect rate as less than 5%. In other studies, mild side 
effects, such as pain, fever or hepatic abscess, were greater. Even 
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Fig. 1. Kaplan-Meier survival based on gender. (A) Males had improved overall survival compared with females (46.0 vs. 22.9 mo; P = 0.026). (B) 
Males had improved disease-free survival compared with females (23.8 vs. 11.3 mo; P = 0.047).
Table 4. Results of the multivariate survival analysis
Variable
Overall survival Progression free survival
P-value Hazard ratio (95% CI) P-value Hazard ratio (95% CI)
Gender 0.292 0.6 (0.2-1.6) 0.190 0.4 (0.1-1.5)
CEA 0.877 0.9 (0.2-5.0) 0.990 1.0 (0.2-4.8)
CA19-9 0.985 0.9 (0.2-4.2) 0.744 1.2 (0.3-4.7)
Extrahepatic disease 0.003 0.1 (0.0-0.5) 0.158 0.5 (0.2-1.3)
Number of hepatic lesions 0.533 1.6 (0.4-7.1)
Location of hepatic lesion 0.045 0.3 (0.1-1.0) 0.018 0.2 (0.0-0.7)
CA, carcinoembryonic antigen; CEA, carcinoembryonic antigen; CI, confidence interval.Journal of The Korean Society of
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Fig. 3. Kaplan-Meier survival based on serum CA19-9 levels. (A) Patients with CA19-9 ≤ 100 U/mL had improved overall survival compared 
with those with CA19-9 > 100 U/mL (44.0 vs. 18.1 mo; P = 0.006). (B) Patients with CA19-9 ≤ 100 U/mL had improved progression-free sur-
vival compared with those with CA19-9 > 100 U/mL (22.5 vs. 9.3 mo; P = 0.037). CA, carcinoembryonic antigen; CEA, carcinoembryonic           
antigen.
though hepatic failure, tumor rupture, damage to blood vessels 
and the biliary tract, thrombosis, and propagation of tumor cells 
via electrodes occurred, their incidence rates were reported as low 
[11, 13] In this study, there were no serious side effects while there 
were two cases of mild fever (5.7%), one case each of hematoma 
and bleeding (2.8%) and no cases of death related to the treatment.
Studies to investigate the effects of RFA treatment have been con-
stantly conducted since it was first initiated. However, investiga-
tions to study the effects of long-term use of RFA have been rare. 
Progression-free survival rates related to localized recurrence in 
the liver have been reported in only a few cases. In addition, stud-
ies of prognostic factors are insufficient. Thus, a purpose of this 
research was to evaluate over five years the effects of RFA by inves-
tigating the five-year overall survival rates and the progression-free 
survival rates and finding related prognostic factors in patients with 
hepatic metastases of colorectal cancers.
According to some studies on local recurrence after RFA, results 
vary from a low rate of recurrence at 3-4% [16, 17] to as high as 
29-55% [18, 19]. The results reported in Korea showed relatively 
high rates at 48-53% [5, 6]. In this study, local recurrence was found 
in 32 patients (91.4%) out of 35 patients, and this high recurrence 
rate is considered to be affected mainly by selection bias of the tar-
get patients, such as size and number of tumors, degree of invasion 
in surrounding tissues, and the presence of micrometastases, by 
technical differences between the surgeons, and by the long dura-
tion of the follow-up.
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Various results on survival rates after RFA of hepatic metastases 
of colorectal cancers have been reported, and the mean survival 
duration was 21 months. The two-year overall survival rate was 
81.5% according to a report by Choi et al. [6] in Korea. The three-
year and the five-year survival rates were 46-68% and 26-44%, re-
spectively, in another study [19-21]. In a recent study conducted 
for 10 years, the mean survival duration was 24 months, the three-
year overall survival rate was 20.2% and the five-year overall sur-
vival rate was 18.4% [22]. There was significant difference in this 
study compared to a previous study with the three-year overall sur-
vival rate at 42.7%, the five-year overall survival rate at 26.0%, and 
the three-year and the five-year progression-free survival rates at 
19.6% and 4.9%, respectively.
Some results from studies on prognostic factors and survival rates 
for RFA have recently been reported. According to a study by Gil-
lams et al. [2] on 309 patients with hepatic metastases of colorectal 
cancers, survival rates were significantly increased after RFA in cases 
where the number of tumors was ≤ 5, their maximal diameters were 
≤ 5 cm, and there were no metastases besides the liver. Also, fac-
tors such as location and clinical stage of the primary carcinoma, 
regimen of chemotherapy and time to hepatic metastases did not 
show any significant relation to survival. Another study showed 
that the survival rate was clinically increased when the number of 
hepatic metastases was ≤ 3 and their maximal diameters were ≤ 3 
cm each, or when CEA was ≤ 200 ng/mL [22]. As a result of a uni-
variate analysis of prognostic factors related to survival rates in this 
study, the progression-free survival rate was significantly increased 
when the hepatic metastasis was a single lesion (P = 0.043). Both 
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Fig. 6. Kaplan-Meier survival based on the location of the hepatic lesion. (A) Patients with a hepatic lesion in one lobe had improved overall sur-
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proved disease-free survival compared with those with hepatic lesions in both lobes (24.4 vs. 6.8 mo; P < 0.001).
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pared with those with multiple hepatic lesions (46.3 vs. 26.9 mo; P = 0.069). (B) Patients with a solitary hepatic lesion had improved disease-free 
survival compared with those with multiple hepatic lesions (25.2 vs. 11.9 mo; P = 0.043).Journal of The Korean Society of
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the overall survival rate and the progression-free survival rate were 
significantly increased when the patient was male (P = 0.026, P = 
0.047), CEA was ≤ 100 ng/mL (P = 0.013, P = 0.006), and CA19-9 
was ≤ 100U/mL (P = 0.006, P = 0.037). Also, when there were no 
metastases in organs besides the liver before RFA (P < 0.001, P = 
0.049) or when the carcinoma was localized in only one lobe of the 
liver (P = 0.001, P < 0.001), the overall survival rate and the pro-
gression-free survival rate were significantly increased. Addition-
ally in a multivariate analysis, patterns similar to those other stud-
ies were shown, where the overall survival rate was significantly 
increased when there were no metastases in organs besides the 
liver before RFA treatment (P = 0.003), and the overall survival 
rates and the progression-free survival rates were significantly in-
creased when the carcinoma was located in only one lobe of the 
liver (P = 0.045, P = 0.018).
In our study, we suggests that RFA may be a safe, simple, and cost-
effective treatment modality; the duration of hospital stay can be 
reduced even though cure cannot be expected in all patients with 
hepatic metastases of colorectal cancers. In addition, a great bene-
fit of RFA is that it can be conducted repeatedly in cases of recur-
rence. This study showed no significant differences in overall sur-
vival rates and progression-free survival rates compared with other 
studies even though the recurrence rate was high, with results show-
ing that gender, CEA, CA19-9, presence of other metastases besides 
liver, and number and location of tumors acted as prognostic fac-
tors. Even though the results of RFA were not compared with the 
results for hepatic resection on patients with hepatic metastases of 
colorectal cancers in this study, RFA isconsidered to be an option 
for treatment when the patient is male, CEA is ≤ 100 ng/mL, CA19-9 
is ≤ 100 U/mL, no metastasis exists in organs other than the liver, 
the hepatic metastasis is a single lesion, and the carcinoma is local-
ized in only one lobe of the liver. In conclusion, we suggest that 
RFA may be a good alternative for surgery with a possibly compa-
rable survival rates for patients of old age and poor general condi-
tion, as well as for patients who refuse surgery.
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